close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

23.93 -0.53 (-2.15%)
Streaming Delayed Price Updated: 12:54 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Recovery Friday
The big winners this week were Financials. 
Via Talk Markets
Biohaven Stock Hits Record High As Migraine Drug Trounces Quarterly Forecasts
Biohaven crushed Wall Street's expectations for second-quarter sales of migraine drug Nurtec on Tuesday, leading BHVN stock to pop. 
Via Investor's Business Daily
Sell Sell Sell
Today the inevitable reversal of wild gains overtook Wall Street, echoing what occurred in major foreign markets Monday. 
Via Talk Markets
People Needed
If qualified people are not looking for work, they will have to be lured to do so with higher wages. 
Via Talk Markets
Teva Recalls One Batch Of Topotecan After Complaint Of Glass Particulate In Vial
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is recalling one lot of its cancer drug topotecan injection after a pharmacy complaint flagged the presence of a single glass... 
Via Benzinga
Topics Product Recall
Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
End Of June
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
Lots Of Deal News
Today Didi, a Chinese ride-hailing stock is doing its IPO reportedly at above the level projected in its application. 
Via Talk Markets
Topics Initial Public Offering
New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly... 
Via Benzinga
JNJ's $260M Settlement Could Serve As Global Opioid Deal Template: Analyst
Over the weekend, Johnson & Johnson (NYSE:JNJ) reached a ... 
Via Benzinga
Teva and Bioeq Announce Commercial Partnership for Biosimilar
From Teva Pharmaceutical Industries Limited
Via Business Wire
Johnson & Johnson Reaches $230M Settlement With New York To End Sale Of Opioids Nationwide
The company has said that it has not marketed opioids in the U.S. since 2015 and discontinued the business in 2020. JNJ did not admit liability in settling with New York State, Nassau, and Suffolk... 
Via Talk Markets
Johnson & Johnson Reaches $230M Settlement With New York State To End Sale Of Opioids Nationwide
On Saturday, Johnson & Johnson (NYSE: JNJ) said it would end the manufacture and sale of opioids nationwide in a $230 million settlement with the New York state,... 
Via Benzinga
Summer Friday
The stock market tried for another record after yesterday's late blowout over the infrastructure deal. 
Via Talk Markets
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults
From Teva Pharmaceutical Industries Limited
Via Business Wire
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
The First Day Of Summer And Prime Day
The bull is back in business today. 
Via Talk Markets
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
Two Rate Hikes In 2023
This afternoon our Fed chief Jerome Powell predicted there will be interest rate hikes faster than before. The news hit US stocks, gold, and bitcoin hard. 
Via Talk Markets
Topics Economy
Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea
From Teva Pharmaceutical Industries Limited
Via Business Wire
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
Happy Friday
The inflation risk is being ignored by the US market now that there will probably not be a tax increase and may be higher prices for longer. 
Via Talk Markets
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
Wednesday News And Catch-Up
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
Fan Hit
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today